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Induced pluripotent stem cells (iPSCs) have the potential to 
differentiate into any cell type of the body. iPSCs are gen-
erated through a process termed “reprogramming,” which 
entails the introduction of a set of transcription factors into 
somatic cells, such as dermal fibroblasts. iPSC clones, rec-
ognizable by their morphology (Figure 1a), arise from these 
cultures, usually within 14–21 days. In addition to their 
pluripotency, another important characteristic of iPSCs 
is that they can be propagated in cell culture indefinitely. 
Thus, an unlimited supply of iPSCs can be generated from 
a small skin biopsy. These iPSCs can then be differentiated 
into different types of somatic cells. For example, iPSCs 
can be directed to differentiate into epidermal keratino-
cytes, one of the cell types often affected in skin disorders. 
iPSC-derived keratinocytes can then be used to generate a 
stratified epidermis, either in vitro (3D skin equivalent cul-
tures) or in vivo (xenotransplantation of keratinocytes onto 
immunodeficient mice; see Koch et al., 2014; Koster et 
al., 2014 for references). The ability to generate unlimited 
numbers of disease-specific keratinocytes provides an ideal 
tool for basic scientists to explore the molecular mecha-
nisms underlying different skin disorders. Further, recently 
developed technologies now enable investigators to correct 
disease-causing mutations in iPSCs. These cells could then 
be used to generate gene-corrected, healthy replacement 
skin for patients affected by genetic skin disorders. A major 
advantage of this approach is that patients would be treated 
with cells that are unlikely to be immunologically rejected.
iPSC GENERATION AND CHARACTERIZATION
iPSCs are most frequently generated from fibroblasts 
obtained from a small (e.g., 4-mm) skin biopsy. A set of 
cDNAs representing four specific genes (“Yamanaka fac-
tors”)—POU5F1 (Oct3/4 in the mouse), SOX2, KLF4, and 
MYC (Takahashi and Yamanaka, 2006)—is then introduced 
into the cells to induce pluripotency. Initially, these repro-
gramming factors were introduced into cells using retrovi-
ral vectors. Although successful, retroviruses integrate into 
the host genome, thus generating mutations. To circumvent 
this problem, nonintegrative systems have been developed 
to introduce reprogramming factors into cells such as plas-
mids, proteins fused to cell-penetrating peptides, mRNAs, 
and nonintegrating Sendai virus vectors (reviewed in 
Schambach et al., 2010). 
ADVANTAGES 
• iPSCs can be generated from skin biopsies.
•  iPSCs can be propagated indefinitely in vitro, 
providing a renewable source of cells.
• iPSCs can be differentiated into any cell type.
•  Cells differentiated from iPSCs can be used for 
disease modeling and drug screening.
•  Disease-causing mutations can be corrected in 
iPSCs.
•  iPSC-derived cells, such as keratinocytes, can be 
used in cell therapy.
•  Generation of iPSCs involves the use of adult cells, 
bypassing ethical concerns associated with using 
embryonic stem cells (ESCs).
LIMITATIONS 
•  iPSCs can acquire genetic mutations during 
reprogramming or in vitro culture.
•  Undifferentiated iPSCs, if transferred to a patient, 
could form tumors (teratomas).
•  More stringent protocols must be developed and 
standardized for the generation, maintenance, 
characterization, and differentiation of iPSCs 
before they can be considered a viable option for 
clinical use.
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differentiation markers such as KRT1 and loricrin. Finally, 
iPSC-derived keratinocytes can form a fully stratified epider-
mis either in vitro (Figures 1g and 1h) or when transplanted 
onto immunodeficient mice. In addition to keratinocytes, 
other components of human skin, such as melanocytes 
and fibroblasts, can also be generated from iPSCs (Ohta et 
al., 2011; Itoh et al., 2013). By combining the three main 
cellular components of human skin, namely keratinocytes, 
fibroblasts, and melanocytes, it should soon be possible to 
regenerate fully functional human skin.  
Beside generating epidermis, iPSC technology can be used 
to generate skin appendages. For example, two groups dem-
onstrated that human iPSC-derived ectodermal precursor 
cells (EPCs) can contribute to the formation of hair follicles 
in vivo (Figure 3; Veraitch et al., 2013; Yang et al., 2014). In 
both studies, human iPSC-derived EPCs were combined with 
trichogenic neonatal mouse dermal papilla cells and then 
transplanted into immunodeficient mice. Several weeks 
later, newly generated hair follicles were observed that 
were, in part, derived from the human EPCs. The tremendous 
advances made in the past two years in this field of research 
suggest that we should soon be able to generate all major 
components of human skin in the laboratory.
APPLICATION OF iPSC TECHNOLOGY IN RESEARCH  
AND THERAPY
One defining property of iPSCs is their ability to be expanded 
indefinitely. The essentially limitless amount of resulting mate-
rial now enables skin researchers to generate human models 
for various genetic skin disorders (reviewed in Koch et al., 
2014; Koster et al., 2014). These models are used not only 
to gain a better understanding of pathological mechanisms 
responsible for various skin disorders but also for the genera-
tion of cell-based screening systems designed to identify com-
pounds that reverse or diminish disease phenotypes (Figure 4).
After the reprogramming factors are introduced, cells with 
morphological characteristics similar to those of embryonic 
stem cells (ESCs) arise (Figure 1a). To determine whether suc-
cessful iPSC conversion has occurred, these putative iPSC 
colonies are evaluated for the expression of genes asso-
ciated with pluripotency, such as NANOG, SSEA-3, and 
TRA1-60 (Figures 1b–d; see also references in Tolar et al., 
2013). Further, the absence of gross genetic abnormalities is 
assessed by karyotype analysis (i.e., a microscopic evalua-
tion of chromosome numbers and structures). Finally, proof 
of pluripotency is obtained by assessing the ability of iPSCs to 
differentiate into cell types representing all three germ layers 
(endoderm, ectoderm, and mesoderm) in vitro or in vivo. For 
example, intramuscular or subcutaneous injection of human 
pluripotent iPSCs into immune-compromised mice will give 
rise to teratomas, tumors composed of cells representing 
each of the three germ layers (Figure 2; Tolar et al., 2013). 
GENERATING KERATINOCYTES FROM iPSCs 
Treatment of iPSCs with retinoic acid and BMP4 in cell cul-
ture directs the differentiation of these stem cells into kera-
tinocytes (Figure 1e) (Itoh et al., 2011; Petrova et al., 2014). 
These cells express well-established keratinocyte markers 
such as KRT14 and TP63 (Figure 1f), and they can be iso-
lated as pure cell populations using fluorescence-activated 
cell sorting with antibodies against keratinocyte cell surface 
markers such as ITGA6 and ITGB4. Further, iPSC-derived 
keratinocytes undergo terminal differentiation upon calcium 
exposure, as demonstrated by the expression of keratinocyte 
Figure 1. Generation of induced pluripotent stem cells (iPSCs) and iPSC-
derived keratinocytes. (a) human iPSC colony. (b–d) Immunofluorescence 
microscopy of iPSC colonies with antibodies against pluripotency markers 
demonstrating that the iPSCs have the typical characteristics of pluripotent 
stem cells (b, NANOG; c, SSEA-3; d, TRA1-60). (e) Micrograph of an iPSC-
derived keratinocyte culture that (f) expresses KRT14 (red) and TP63 (green), 
two marker proteins for keratinocytes. (g, h) 3D skin equivalent generated from 
human iPSC-derived keratinocytes. The sections were stained with antibodies 
against (g) LOR (loricrin; green) and KRT14 (red) and (h) DSC3 (desmocollin 3; 
green) and KRT14 (red), proteins expressed in normal human epidermis.
Figure 2. Induced pluripotent stem cell (iPSC)-induced teratoma in an 
immunodeficient mouse. Note that the iPSCs differentiated into cells 
representing mesodermal, ectodermal, and endodermal lineages. Reprinted 
with permission from Tolar et al., 2013.
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One therapeutic goal is to utilize iPSC technology to gener-
ate genetically corrected keratinocytes from patients affected 
by genetic skin disorders. For example, Tolar and colleagues 
(Tolar et al., 2013) recently demonstrated that gene-corrected 
iPSCs can be generated from the skin of patients with a 
mosaic form of recessive dystrophic epidermolysis bullosa 
(RDEB). RDEB is caused by mutations in COL7A1, the gene 
encoding collagen VII. These mutations prevent the synthesis 
of sufficient amounts of collagen VII, leading to skin blister-
ing. The patient described by Tolar and colleagues exhibited 
patches of normal-appearing skin in which the COL7A1 gene 
was spontaneously corrected (Figure 5a and b). By generating 
iPSCs and, subsequently, iPSC-derived keratinocytes from 
these patches (Figure 5e), the authors were able to provide 
proof of principle that iPSC technology can be used to gen-
erate essentially unlimited amounts of clinically normal 
epidermis from patients with a mosaic form of RDEB. 
Despite its potential use for patients with mosaic forms 
of skin disorders, this approach is not applicable to patients 
with nonmosaic skin disorders. For the latter group of skin 
disorders, genetic mutations must be corrected in vitro to 
generate healthy replacement skin. This can be accom-
plished using sequence-specific DNA nucleases (e.g., TALE 
nucleases; Miller et al., 2011) designed to cut specific DNA 
sequences. If these nucleases are simultaneously introduced 
into patient-derived cells with a plasmid containing the cor-
rected DNA sequence, homologous recombination leads 
to the repair of disease-causing point mutations (see refer-
ences in Koch et al., 2014; Koster et al., 2014). The resulting 
gene-corrected iPSCs constitute an ideal source for generat-
ing unlimited supplies of patient-specific (and therefore most 
likely immunologically well-tolerated), healthy skin grafts. 
These gene corrections can be done either in iPSCs or in 
primary patient cells. For example, Osborn and colleagues 
(Osborn et al., 2013) recently corrected an RDEB-causing 
COL7A1 mutation in patient fibroblasts. These fibroblasts 
were then turned into iPSCs and subsequently into keratino-
cytes expressing collagen VII, suggesting that this technology 
could indeed be used to treat genodermatoses with healthy 
(gene-corrected) patient-derived replacement tissue.
SUMMARY AND CONCLUSIONS
iPSCs combined with gene-editing technologies are poised 
to have a significant impact on our ability to generate in 
vitro and in vivo disease models for genodermatoses caused 
by single point mutations. Generating keratinocytes that are 
genetically identical except for the presence or absence of 
Figure 3. Generation of skin appendages with induced pluripotent stem cell (iPSC)-derived ectodermal precursor cells. (a) Morphology of hair follicles (HFs) 
formed in areas transplanted with human iPSC-derived ectodermal precursor cells (hiPSC-EPCs). (b) Pilosebaceous unit (HF and sebaceous gland) formed with 
participation of hiPSC-EPCs. (c) Normal mouse HF control. (d–f) Staining of HF with a human-specific antibody. (d) Human HF and (e) hiPSC-EPC-derived HF 
stain positive, whereas the mouse HF (f) is negative. Bars = 50 mm. Reprinted with permission from Veraitch et al., 2013.
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Figure 4. Outline of the basic principles underlying induced pluripotent stem 
cell (iPSC) technology as it is used for disease modeling and for the generation 
of replacement tissue in regenerative medicine. Somatic cells (e.g., biopsy-
derived fibroblasts) are reprogrammed into iPSCs. Using genome-editing tools, 
such as TALE nucleases, point mutations can be corrected in the iPSCs (or in 
the original fibroblasts; see text for details). iPSCs can be differentiated into 
keratinocytes. Gene-corrected (control) and clinically affected keratinocytes 
can then be used in several experimental approaches: to set up compound 
screening to identify drugs interfering with disease phenotypes or to model 
clinical skin phenotypes in vitro (organotypic culture) or in vivo (generation 
of a human epidermis in immunodeficient mice, xenotransplants). Finally, 
gene-corrected keratinocytes can be used to produce replacement tissue for 
patients, for example, for patients with genetic blistering diseases (e.g., recessive 
dystrophic epidermolysis bullosa, see text for details).
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a disease-causing mutation will provide researchers with 
ideal systems to assess defects in iPSC-derived patient kera-
tinocytes at the RNA, protein, and functional levels. Further, 
this approach will enable us to develop patient cell–based 
screening systems to identify compounds capable of cor-
recting defects in patient keratinocytes. In the long term, this 
technology may also be used to generate patient-derived, 
gene-corrected skin that could be transplanted onto patients 
from whom the original iPSCs were derived. Thus, this may 
lead to the development of novel therapies for debilitating 
genetic skin diseases, such as skin blistering or skin fragility 
disorders, for which no current therapies exist.
Although the research potential of iPSCs is without doubt 
significant, there are still concerns regarding the safety of 
using this technology for patient care. For example, introduc-
tion of undifferentiated iPSCs into patients could lead to the 
formation of teratomas. Further, prolonged culture has the 
potential to introduce mutations into the iPSC genome. To 
overcome these concerns, methods are under development 
that allow for the generation of pure populations of target 
cells, such as keratinocytes, that do not contain undifferenti-
ated iPSCs. Further, approaches such as deep sequencing can 
be utilized to identify mutations in iPSCs before they are used 
therapeutically. Finally, the generation and genetic manipu-
lation of iPSCs require the introduction of recombinant 
DNA into these cells. Efficient methods to introduce DNA 
into cells without leaving a genetic footprint are required. 
Nevertheless, the clinical use of iPSC-based technology is 
rapidly approaching, as demonstrated by a clinical trial at 
the RIKEN Center for Developmental Biology in Japan, in 
which patients will be treated with iPSC-derived retinal pig-
ment epithelium cells for age-related macular degeneration 
(Cyranoski, 2013).
Figure 5. Generation of phenotypically normal keratinocytes from patients 
affected by a mosaic form of recessive dystrophic epidermolysis bullosa 
(RDEB) using induced pluripotent stem cell (iPSC) technology.  
(a) Child with a mosaic form of generalized severe RDEB. The arrow points to 
a clinically normal skin area shown at higher magnification in (b).  
(c) Immunofluorescence microscopy demonstrates the absence of collagen 
VII staining in the affected skin of the patient, whereas (d) clinically normal 
areas show collagen VII at the epidermal–dermal junction. (e) iPSC-derived 
teratoma containing an epidermal-like structure expressing collagen VII 
at the dermal–epidermal junction, demonstrating that the iPSC-derived 
keratinocytes that originated from cells in the clinically normal skin of the 
patient produce collagen VII (collagen VII staining in red, nuclei are stained 
in blue). Bars = 50 mm. Reprinted with permission from Tolar et al., 2013.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit.  
To take the quiz, with or without CME credit, follow the link under  
the “CME ACCREDITATION” heading.
A.  ESC-like cellular and colony morphology.
B.  Ability to be expanded indefinitely.
C.  Ability to differentiate into different cell types.
D.  All of the above.
A.  Cells differentiated from iPSCs are unlikely to  
be immunologically rejected when used in 
autologous cell-replacement therapies.
B.  iPSCs are not tumorigenic and do not form 
teratomas.
C.  iPSCs are easier to maintain in culture than ESCs.
D.  iPSCs differentiate more efficiently than ESCs.
A.  Fusion between a somatic cell and embryonic  
stem cell.
B.  Transplantation of a nucleus from a somatic cell 
into an enucleated egg.
C.  Collection of cells from the inner cell mass of  
a blastocyst.
D.  Ectopic expression of reprogramming factors  
converting somatic cells to stem cells.
1.  How are iPSCs generated?
2.  What are some criteria used to define iPSCs?
3.  List a main advantage of iPSC technology.
4.  What is one potential use for iPSCs?
5.  What is an issue of concern when considering iPSCs 
for use in clinical applications?
A.  iPSCs can prevent tumor formation.
B.  iPSCs can be used to cure everything.
C.  iPSC-derived cells can be used to screen for  
novel compounds for the treatment of specific  
disorders.
D.  iPSCs can be used effectively when added to  
antiaging skin creams.
A. Gene correction cannot be performed in iPSCs.
B.  iPSCs may acquire genetic mutations while being 
expanded in vitro.
C.  Cells differentiated from iPSCs may outcompete 
host cells of the same type after transplantation.
D.  After a period of time, cells differentiated from 
iPSCs revert to their pluripotent state.
© 2014 The Society for Investigative Dermatology www.jidonline.org 5
RESEARCH TECHNIQUES MADE SIMPLE  
ACKNOWLEDGMENTS
The authors thank the University of Colorado School of Medicine iPSC 
(http://www.medschool.ucdenver.edu/iPS) and Histology Cores for technical 
support. Histological services were supported by National Institutes of Health 
grant P30 AR057212. JD is supported by a predoctoral fellowship from the 
Colorado Clinical & Translational Science Institute (TR001081). PJK and 
MIK are supported by grants from the National Foundation for Ectodermal 
Dysplasias and the National Institute of Arthritis and Musculoskeletal 
and Skin Diseases under award numbers R01 AR061506 (MIK) and RO1 
AR053892 (PJK). The content of this article is solely the responsibility of the 
authors and does not necessarily represent the official views of the National 
Institutes of Health.
CONFLICT OF INTEREST
The authors state no conflict of interest.
CME ACCREDITATION
This activity has been planned and implemented in accordance with the 
Essential Areas and Policies of the Accreditation Council for Continuing 
Medical Education through the joint sponsorship of the Duke University 
School of Medicine and Society for Investigative Dermatology. The Duke 
University School of Medicine is accredited by the ACCME to provide 
continuing medical education for physicians. To participate in the CME 
activity, follow the link provided. Physicians should only claim credit 
commensurate with the extent of their participation in the activity.
To take the online quiz, follow the link below: 
http://continuingeducation.dcri.duke.edu/research-techniques-made-simple-
journal-based-cme-1
SUPPLEMENTARY MATERIAL
A PowerPoint slide presentation appropriate for teaching purposes is available 
at http://dx.doi.org/10.1038/jid.2014.238.
REFERENCES
Cyranoski D (2013) Stem cells cruise to clinic. Nature 494:413
Itoh M, Kiuru M, Cairo MS et al. (2011) Generation of keratinocytes from normal 
and recessive dystrophic epidermolysis bullosa-induced pluripotent stem 
cells. Proc Natl Acad Sci USA 108:8797–802
Itoh M, Umegaki-Arao N, Guo Z et al. (2013) Generation of 3D skin equivalents 
fully reconstituted from human induced pluripotent stem cells (iPSCs). PLoS 
One 8:e77673
Koch PJ, Dinella J, Fete M et al. (2014) Modeling AEC—new approaches to study 
rare genetic disorders. Am J Med Gen A; e-pub ahead of print 24 March 2014
Koster MI, Dinella J, Chen J et al. (2014) Integrating animal models and in vitro 
tissue models to elucidate the role of desmosomal proteins in diseases. Cell 
Commun Adhes 21:55–63
Miller JC, Tan S, Qiao G et al. (2011) A TALE nuclease architecture for efficient 
genome editing. Nat Biotechnol 29:143–8
Ohta S, Imaizumi Y, Okada Y et al. (2011) Generation of human melanocytes 
from induced pluripotent stem cells. PLoS One 6:e16182
Osborn MJ, Starker CG, McElroy AN et al. (2013) TALEN-based gene correction 
for epidermolysis bullosa. Mol Ther 21:1151–9
Petrova A, Celli A, Arno M et al. (2014) 3D in vitro model of a functional 
epidermal permeability barrier from hESC and iPSC. J Invest Dermatol 
134:S71
Schambach A, Cantz T, Baum C et al. (2010) Generation and genetic modification 
of induced pluripotent stem cells. Expert Opin Biol Ther 10:1089–103
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126:663–76
Tolar J, McGrath JA, Xia L et al. (2013) Patient-specific naturally gene-reverted 
induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. 
J Invest Dermatol 134:1246–54
Veraitch O, Kobayashi T, Imaizumi Y et al. (2013) Human induced pluripotent 
stem cell-derived ectodermal precursor cells contribute to hair follicle 
morphogenesis in vivo. J Invest Dermatol 133:1479–88
Yang R, Zheng Y, Burrows M et al. (2014) Generation of folliculogenic human 
epithelial stem cells from induced pluripotent stem cells. Nat Commun 
5:3071
